You might not have noticed it, but AbbVie (NYSE: ABBV) is on a roll -- at least when it comes to winning drug approvals. Since the beginning of 2019, the big biotech has racked up U.S. Food and Drug ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results